Lotus Aortic Valve System is Boston Scientific’s second-generation transcatheter aortic valve replacement (TAVR) technology.

As per the agreement, Sorin Group will undertake certain manufacturing steps related to the tissue valve in its Canadian facility.

Sorin Group Cardiac Surgery Business Unit president Michel Darnaud said, "This agreement recognizes the strong valve manufacturing experience that Sorin Group has accumulated across its European and North American operations."

"Building on more than 40 years of innovation, development, clinical validation and commercialization in the field of mechanical and tissue prosthetic heart valves," Darnaud added.

The Lotus Aortic Valve System is an investigational device and not available for sale.